The Ultimate Industry Forum for Obesity & Weight Loss
The 3rd Obesity & Weight Loss Drug Development Summit in 2025 is poised to ignite the field. Building upon the newly-released Lancet Commission to redefine the landscape, the summit will dissect the future of obesity research, policy and therapeutic development.
Navigate the updated regulatory guidelines and unlock the potential of personalized medicine and precision therapies.
Confront the challenge of side effects head-on by exploring novel targets and optimizing treatment outcomes with innovative combination therapies.
Hear from 22+ industry luminaries and thought leaders, from companies such as Novartis, Regeneron and Biolexis who are pushing the boundaries of obesity treatment.
This is your opportunity to be at the forefront of this critical endeavour as obesity rates soar and accelerate the development of life-changing therapies.
Agenda Highlights:
The Lancet Commission's Roadmap and Navigating the Evolving Regulatory Landscape: Gain better understanding of the Commission's key findings and recommendations, alongside, the regulatory updates and their implications for drug development and market access.
Solving Muscle Mass Preservation: The summit will emphasize the critical importance of preserving muscle mass during weight loss. Gain insights into strategies being developed for mitigating muscle loss, including the exploration of novel therapeutic targets.
Unlocking Personalized Treatment Strategies: Gather insights into cutting-edge approaches for personalizing obesity treatment through the development of alternative administration routes and differing modalities. This will enable the tailoring of treatment plans to individual patient needs, optimizing outcomes.
Targeting Side Effects with Innovative Solutions: The showcasing of novel targets and combination therapies designed to manage side effects effectively will allow the exploration of strategies for improving tolerability, treatment continuation and overall patient experience.
Forging Powerful Partnerships: With 70+ industry experts from companies such as Zealand, Prive Bio and Novartis, the Summit will foster collaboration and knowledge sharing among leading researchers, clinicians, and industry executives in the obesity space that can accelerate the development of transformative weight loss therapies.
Who Will You Meet?
This summit is essential for senior leaders in the obesity space from pharmaceutical giants to biotechnology innovators, including scientists in obesity, diabetes and cardiovascular-related fields as well as drug discovery and medical affairs experts. With the ability to gain insights from 22+ renowned speakers and network with key decision-makers from 20+ leading companies such as Eli Lilly, Novo Nordisk, and Boehringer Ingelheim, shaping the future of obesity treatment.
What Your Peers Have to Say
“This looks to be a great forum for pharma and biotech to learn from each other with the goal of treating the human disease of obesity”
Associate Director, Eli Lilly
‘’This Summit will give me chance to discuss science and drug discovery with big players in the field of obesity. It is also a big networking opportunity.”
Lab Head, Boehringer Ingelheim